Pfizer: oral antiviral treatment against Covid-19 in trial

Magazine Issue:

The insurance business in the post-Covid-19 era [3]

Magazine date:

Mar 2021

medicament The pharmaceutical company Pfizer has begun the phase 1 trials of an antiviral treatment against Covid-19. Administered orally, the new drug is to be used as soon as the first symptoms of SARS-CoV-2 appear.

The antiviral agent inhibits the reproduction of the virus in the cells according to a process known in anti-HIV and hepatitis C treatments.

Alongside this first treatment, Pfizer is also launching the phase 1 trials of a second treatment administered intravenously. The tests are being conducted on patients hospitalized with Covid-19.

Fri, 26/03/2021 - 09:41

Links:
[1] https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.atlas-mag.net%2Fen%2Farticle%2Fpfizer-oral-antiviral-treatment-against-covid-19-in-trial&text=Pfizer%3A+oral+antiviral+treatment+against+Covid-19+in+trial
[2] https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fwww.atlas-mag.net%2Fen%2Farticle%2Fpfizer-oral-antiviral-treatment-against-covid-19-in-trial&source=Atlas Magazine&mini=true
[3] https://www.atlas-mag.net/en/issue/insurance-in-the-aftermath-of-covid-19
[4] https://www.atlas-mag.net/en/article/covid-19-vaccine-ranking-of-countries-per-doses-administered